Earlier today, the Cato Institute and I filed an amicus brief in Burlap and Barrel, Inc. v. Trump, one of the cases challenging Trump's massive new Section 122 tariffs before the US Court of ...

Filing in 10th Circuit Highlights Need for Oversight of Runaway PBM and Contract Pharmacy Profiteering WASHINGTON, DC, UNITED STATES, April 2, 2026 /EINPresswire.com ...

Unfortunately you only have a number of days left to watch a legendary horror franchise, kids' TV classic and an acclaimed sci-fi series. So you don't have very long to catch up on Scream, Scream 2 or ...

March 10 (Reuters) - Microsoft (MSFT.O), opens new tab filed on Tuesday a brief in support of Anthropic's lawsuit asking the court to temporarily block the U.S. Department of Defense's designation of ...

The amicus brief was the latest barb in negotiations with the Department of Defense. The amicus brief was the latest barb in negotiations with the Department of Defense. On Monday, Anthropic filed its ...

This month brings a malign quarterback, a naughty robot hottie and the grim reaper himself. By Erik Piepenburg Stream it on Peacock. I’m in the minority when it comes to Justin Tipping’s critically ...

Washington, D.C. – U.S. Senator Ron Wyden, D-Ore., and Alex Padilla, D-Calif., today announced they are leading their colleagues in filing an amicus brief in Watson v. Republican National Committee, a ...

From genre-defining hits ('Sinners') and surprise breakouts ('Weapons') to hidden gems ('Dead Mail') and auteur-driven awards contenders ('Frankenstein'), these were the best scares studios and ...

Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic liver disease candidate it had once hoped would become a best-in-class treatment. The oral ...

BioMarin Pharmaceutical said on ⁠Friday it would acquire Amicus ‍Therapeutics ‍for about $4.8 ‍billion, expanding its presence in rare metabolic diseases. The ‍drugmaker will ‍pay $14.50 per share for ...

Sixteen months after luring former Roche dealmaker James Sabry, M.D., Ph.D., out of retirement and signaling a shift in its business development approach, BioMarin has announced the largest ...